{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:22:32Z","timestamp":1790673752710,"version":"4.1.0"},"reference-count":71,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD21\/0002\/0041"],"award-info":[{"award-number":["RD21\/0002\/0041"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Dry eye disease (DED) is a common and very symptomatic pathology that affects normal daily activity. The aim of the study was to evaluate the efficacy of plasma rich in growth factors (PRGF) added to one routine treatment protocol for DED (artificial tears substitutes, lid hygiene, and anti-inflammatory therapy). Materials and Methods: Patients were divided into two groups of treatment: standard treatment group (n = 43 eyes) and PRGF group (n = 59). Patients\u2019 symptomatology (inferred from OSDI and SANDE questionnaires), ocular inflammation, tear stability, and ocular surface damage were analyzed at baseline and after 3 months of treatment. Results: OSDI test scores were significantly lower in both groups (p &lt; 0.001). SANDE frequency test scores also improved statistically, with differences between groups (p = 0.0089 SANDE frequency and p &lt; 0.0119 SANDE severity). There was a greater reduction in ocular redness (ocular inflammation) in the PRGF group (p &lt; 0.0001) and fluorescein tear break-up time was significantly improved in the PRGF group (p = 0.0006). No significant changes were found in terms of ocular surface damage. No adverse events were obtained in either group. Conclusions: The addition of PRGF to the standard treatment of DED, according to the results obtained, proved to be safe and produced an improvement in ocular symptomatology and signs of inflammation, particularly in moderate and severe cases, when compared to standard treatment.<\/jats:p>","DOI":"10.3390\/medicina59050928","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T02:36:59Z","timestamp":1683859019000},"page":"928","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Impact of Plasma Rich in Growth Factors (PRGF) Eye Drops on Ocular Redness and Symptomatology in Patients with Dry Eye Disease"],"prefix":"10.3390","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5306-1921","authenticated-orcid":false,"given":"Javier","family":"Lozano-Sanroma","sequence":"first","affiliation":[{"name":"Instituto Oftalmol\u00f3gico Fern\u00e1ndez-Vega, 33012 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4976-3792","authenticated-orcid":false,"given":"Alberto","family":"Barros","sequence":"additional","affiliation":[{"name":"Instituto Oftalmol\u00f3gico Fern\u00e1ndez-Vega, 33012 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6051-9240","authenticated-orcid":false,"given":"Ignacio","family":"Alcalde","sequence":"additional","affiliation":[{"name":"Instituto Universitario Fern\u00e1ndez-Vega, Fundaci\u00f3n de Investigaci\u00f3n Oftalmol\u00f3gica, Universidad de Oviedo, 33012 Oviedo, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5884-6741","authenticated-orcid":false,"given":"Ronald M.","family":"S\u00e1nchez-\u00c1vila","sequence":"additional","affiliation":[{"name":"Regenerative Medicine Laboratory, Biotechnology Institute (BTI), 01007 Vitoria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Queiruga-Pi\u00f1eiro","sequence":"additional","affiliation":[{"name":"Instituto Oftalmol\u00f3gico Fern\u00e1ndez-Vega, 33012 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Fern\u00e1ndez-Vega Cueto","sequence":"additional","affiliation":[{"name":"Instituto Oftalmol\u00f3gico Fern\u00e1ndez-Vega, 33012 Oviedo, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain"},{"name":"Department of Surgery and Medical-Surgical Specialties, Universidad de Oviedo, 33006 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Merayo-Lloves","sequence":"additional","affiliation":[{"name":"Instituto Oftalmol\u00f3gico Fern\u00e1ndez-Vega, 33012 Oviedo, Spain"},{"name":"Instituto Universitario Fern\u00e1ndez-Vega, Fundaci\u00f3n de Investigaci\u00f3n Oftalmol\u00f3gica, Universidad de Oviedo, 33012 Oviedo, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain"},{"name":"Department of Surgery and Medical-Surgical Specialties, Universidad de Oviedo, 33006 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Tsubota, K., Pflugfelder, S.C., Liu, Z., Baudouin, C., Kim, H.M., Messmer, E.M., Kruse, F., Liang, L., Carreno-Galeano, J.T., and Rolando, M. (2020). Defining Dry Eye from a Clinical Perspective. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239271"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II Epidemiology Report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul. Surf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II Definition and Classification Report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul. Surf."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","article-title":"Tfos dews II Pathophysiology Report","volume":"15","author":"Bron","year":"2017","journal-title":"Ocul. Surf."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/02713683.2022.2039205","article-title":"Management Strategies for Evaporative Dry Eye Disease and Future Perspective","volume":"47","year":"2022","journal-title":"Curr. Eye Res."},{"key":"ref_6","unstructured":"Bron, A.J. (2015). Dry Eye: A Practical Approach, Springer."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"Tfos Dews II Management and Therapy Report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocul. Surf."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.0958-7578.2005.00559.x","article-title":"Topical Treatment of Ocular Surface Defects: Comparison of the Epitheliotrophic Capacity of Fresh Frozen Plasma and Serum on Corneal Epithelial Cells in an in Vitro Cell Culture Model","volume":"15","author":"Hartwig","year":"2005","journal-title":"Transfus. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1111\/j.0041-1132.2004.04079.x","article-title":"Epitheliotrophic Capacity of a Growth Factor Preparation Produced from Platelet Concentrates on Corneal Epithelial Cells: A Potential Agent for the Treatment of Ocular Surface Defects?","volume":"44","author":"Hartwig","year":"2004","journal-title":"Transfusion"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1167\/iovs.05-0876","article-title":"Corneal Epitheliotrophic Capacity of Three Different Blood-Derived Preparations","volume":"47","author":"Liu","year":"2006","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.bbmt.2016.05.023","article-title":"A Single-Center Pilot Prospective Study of Topical Application of Platelet-Derived Eye Drops for Patients with Ocular Chronic Graft-versus-Host Disease","volume":"22","author":"Zallio","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"8406832","DOI":"10.1155\/2016\/8406832","article-title":"The Effect of Autologous Platelet Lysate Eye Drops: An In Vivo Confocal Microscopy Study","volume":"2016","author":"Fea","year":"2016","journal-title":"BioMed Res. Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e605","DOI":"10.1111\/aos.12710","article-title":"Autologous Serum and Plasma Rich in Growth Factors in Ophthalmology: Preclinical and Clinical Studies","volume":"93","author":"Anitua","year":"2015","journal-title":"Acta Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1001\/archopht.1975.01010020815015","article-title":"Clinical Experience with a Mobile Ocular Perfusion Pump","volume":"93","author":"Ralph","year":"1975","journal-title":"Arch. Ophthalmol."},{"key":"ref_15","first-page":"CD009327","article-title":"Autologous Serum Eye Drops for Dry Eye","volume":"2017","author":"Pan","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/S0161-6420(99)90412-8","article-title":"Treatment of Persistent Corneal Epithelial Defect by Autologous Serum Application","volume":"106","author":"Tsubota","year":"1999","journal-title":"Ophthalmology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.exer.2013.12.005","article-title":"Effects of Heat-Treatment on Plasma Rich in Growth Factors-Derived Autologous Eye Drop","volume":"119","author":"Anitua","year":"2014","journal-title":"Exp. Eye Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6066","DOI":"10.1167\/iovs.11-7302","article-title":"Plasma Rich in Growth Factors (PRGF-Endoret) Stimulates Proliferation and Migration of Primary Keratocytes and Conjunctival Fibroblasts and Inhibits and Reverts TGF-\u03921\u2013Induced Myodifferentiation","volume":"52","author":"Anitua","year":"2011","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/ICO.0b013e31803dcda2","article-title":"Interleukin-6 and Tumor Necrosis Factor-\u03b1 Levels in Tears of Patients With Dry Eye Syndrome","volume":"26","author":"Yoon","year":"2007","journal-title":"Cornea"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1076\/ceyr.19.3.201.5309","article-title":"Altered Cytokine Balance in the Tear Fluid and Conjunctiva of Patients with Sjogren\u2019s Syndrome Keratoconjunctivitis Sicca","volume":"19","author":"Pflugfelder","year":"1999","journal-title":"Curr. Eye Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.tripleo.2005.03.007","article-title":"The Effect of Platelet-Rich Plasma on the Cellular Response of Rat Bone Marrow Cells in Vitro","volume":"100","author":"Ogino","year":"2005","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodontol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jconrel.2011.07.004","article-title":"Perspectives and Challenges in Regenerative Medicine Using Plasma Rich in Growth Factors","volume":"157","author":"Anitua","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000100933","article-title":"Symptomatic Dry Eye Treatment with Autologous Platelet-Rich Plasma","volume":"39","author":"Alio","year":"2007","journal-title":"Ophthalmic Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1097\/ICO.0b013e31820d86d6","article-title":"Efficacy of Plasma Rich in Growth Factors for the Treatment of Dry Eye","volume":"30","author":"Morales","year":"2011","journal-title":"Cornea"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/00003226-200310000-00008","article-title":"Grading of Corneal and Conjunctival Staining in the Context of Other Dry Eye Tests","volume":"22","author":"Bron","year":"2003","journal-title":"Cornea"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.exer.2015.02.016","article-title":"Plasma Rich in Growth Factors (PRGF) Eye Drops Stimulates Scarless Regeneration Compared to Autologous Serum in the Ocular Surface Stromal Fibroblasts","volume":"135","author":"Anitua","year":"2015","journal-title":"Exp. Eye Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000444496","article-title":"Safety and Efficacy of Autologous Plasma Rich in Growth Factors Eye Drops for the Treatment of Evaporative Dry Eye","volume":"56","author":"Riestra","year":"2016","journal-title":"Ophthalmic Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/09273940701486803","article-title":"Ocular Surface Disease Index for the Diagnosis of Dry Eye Syndrome","volume":"15","author":"Aydin","year":"2007","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S1542-0124(12)70053-8","article-title":"Development and Validation of a Short Global Dry Eye Symptom Index","volume":"5","author":"Schaumberg","year":"2007","journal-title":"Ocul. Surf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e8149","DOI":"10.5867\/medwave.2021.03.8149","article-title":"Minimal Clinically Important Difference: The Basics","volume":"21","author":"Meza","year":"2021","journal-title":"Medwave"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/j.clae.2012.08.058","article-title":"Objective Classification and Documentation of Bulbar Redness Using a Corneal Topographer","volume":"35","author":"Jerchel","year":"2012","journal-title":"Contact Lens Anterior Eye"},{"key":"ref_32","first-page":"340","article-title":"Automated Measurement of Bulbar Redness","volume":"43","author":"Fieguth","year":"2002","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1167\/iovs.13-12217","article-title":"The Ocular Redness Index: A Novel Automated Method for Measuring Ocular Injection","volume":"54","author":"Amparo","year":"2013","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1097\/OPX.0000000000000643","article-title":"Assessment of Bulbar Redness with a Newly Developed Keratograph","volume":"92","author":"Wu","year":"2015","journal-title":"Optom. Vis. Sci."},{"key":"ref_35","first-page":"478","article-title":"Comparison of the Schirmer I Test with and without Topical Anesthesia for Diagnosing Dry Eye","volume":"5","author":"Li","year":"2012","journal-title":"Int. J. Ophthalmol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/bjo.83.1.89","article-title":"Diseases Associated with Ocular Surface Abnormalities: The Importance of Reflex Tearing","volume":"83","author":"Tsubota","year":"1999","journal-title":"Br. J. Ophthalmol."},{"key":"ref_37","unstructured":"(2022, August 23). Cambridge University Effect Size Calculator. Available online: https:\/\/www.cem.org\/effect-size-calculator."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/jpepsy\/jsp004","article-title":"How to Select, Calculate, and Interpret Effect Sizes","volume":"34","author":"Durlak","year":"2009","journal-title":"J. Pediatr. Psychol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"319","DOI":"10.5935\/0034-7280.20170067","article-title":"The Use of Platelet Rich-Plasma in Ophthalmology: A Literature Review","volume":"76","author":"Ribeiro","year":"2017","journal-title":"Rev. Bras. Oftalmol."},{"key":"ref_40","first-page":"e170","article-title":"Efficacy and Safety of Treatment of Hyposecretory Dry Eye with Platelet-Rich Plasma","volume":"97","author":"Molina","year":"2019","journal-title":"Acta Ophthalmol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/ICO.0b013e3181a81820","article-title":"Plasma Rich in Growth Factors as a Therapeutic Agent for Persistent Corneal Epithelial Defects","volume":"29","author":"Morales","year":"2010","journal-title":"Cornea"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Idoipe, M., de la Sen-Corcuera, B., S\u00e1nchez-\u00e1vila, R.M., S\u00e1nchez-p\u00e9rez, C., Satu\u00e9, M., S\u00e1nchez-p\u00e9rez, A., Orive, G., Muruzabal, F., Anitua, E., and Pablo, L. (2021). Membrane of Plasma Rich in Growth Factors in Primary Pterygium Surgery Compared to Amniotic Membrane Transplantation and Conjunctival Autograft. J. Clin. Med., 10.","DOI":"10.3390\/jcm10235711"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000439280","article-title":"Autologous Plasma Rich in Growth Factors Eyedrops in Refractory Cases of Ocular Surface Disorders","volume":"55","author":"Sanchez","year":"2016","journal-title":"Ophthalmic Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/ICO.0b013e31818c69ef","article-title":"Efficacy of Combined 0.05% Cyclosporine and 1% Methylprednisolone Treatment for Chronic Dry Eye","volume":"31","author":"Byun","year":"2012","journal-title":"Cornea"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/ICL.0000000000000049","article-title":"Effect of Loteprednol Etabonate 0.5% on Initiation of Dry Eye Treatment With Topical Cyclosporine 0.05%","volume":"40","author":"Sheppard","year":"2014","journal-title":"Eye Contact Lens Sci. Clin. Pract."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1167\/iovs.10-6997g","article-title":"The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on Management and Treatment of Meibomian Gland Dysfunction","volume":"52","author":"Geerling","year":"2011","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/ICL.0000000000000236","article-title":"Efficacy and Safety of 0.2% Hyaluronic Acid in the Management of Dry Eye Disease","volume":"43","year":"2017","journal-title":"Eye Contact Lens Sci. Clin. Pract."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/bjophthalmol-2011-301448","article-title":"A Randomised, Double-Masked Comparison Study of Diquafosol versus Sodium Hyaluronate Ophthalmic Solutions in Dry Eye Patients","volume":"96","author":"Takamura","year":"2012","journal-title":"Br. J. Ophthalmol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.ophtha.2012.12.022","article-title":"A Randomized, Multicenter Phase 3 Study Comparing 2% Rebamipide (OPC-12759) with 0.1% Sodium Hyaluronate in the Treatment of Dry Eye","volume":"120","author":"Kinoshita","year":"2013","journal-title":"Ophthalmology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/OPX.0000000000000101","article-title":"Effects of Sodium Hyaluronate on Wavefront Aberrations in Dry Eye Patients","volume":"91","author":"Lekhanont","year":"2014","journal-title":"Optom. Vis. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/archophthalmol.2011.364","article-title":"Dry Eye Disease","volume":"130","author":"Stevenson","year":"2012","journal-title":"Arch. Ophthalmol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.preteyeres.2012.02.003","article-title":"Ocular Surface Immunity: Homeostatic Mechanisms and Their Disruption in Dry Eye Disease","volume":"31","author":"Barabino","year":"2012","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/09273948.2019.1682618","article-title":"Should We Reconsider the Classification of Patients with Dry Eye Disease?","volume":"29","author":"Rolando","year":"2021","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0161-6420(99)90171-9","article-title":"Topical Nonpreserved Methylprednisolone Therapy for Keratoconjunctivitis Sicca in Sj\u00f6gren Syndrome","volume":"106","author":"Marsh","year":"1999","journal-title":"Ophthalmology"},{"key":"ref_55","first-page":"687","article-title":"Key Factors in the Subjective and Objective Assessment of Conjunctival Erythema","volume":"41","author":"Papas","year":"2000","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/00006324-198704000-00003","article-title":"Assessment of Conjunctival Hyperemia in Contact Lens Wearers. Part I","volume":"64","author":"McMonnies","year":"1987","journal-title":"Optom. Vis. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1046\/j.1475-1313.1999.00420.x-i1","article-title":"Validation of Grading Scales for Contact Lens Complications","volume":"21","author":"Efron","year":"2001","journal-title":"Ophthalmic Physiol. Opt."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clae.2006.12.003","article-title":"Comparison of an Objective Method of Measuring Bulbar Redness to the Use of Traditional Grading Scales","volume":"30","author":"Sorbara","year":"2007","journal-title":"Contact Lens Anterior Eye"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1136\/bjo.2006.112680","article-title":"Sensitivity and Reliability of Objective Image Analysis Compared to Subjective Grading of Bulbar Hyperaemia","volume":"91","author":"Peterson","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Barros, A., Lozano-Sanroma, J., Queiruga-Pi\u00f1eiro, J., Fern\u00e1ndez-Vega Cueto, L., Anitua, E., Alcalde, I., and Merayo-Lloves, J. (2023). Recovery of Corneal Innervation after Treatment in Dry Eye Disease: A Confocal Microscopy Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12051841"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Anitua, E., de la Fuente, M., Merayo-Lloves, J., and Muruzabal, F. (2022). Optimization of a Plasma Rich in Growth Factors Membrane for the Treatment of Inflammatory Ocular Diseases. Bioengineering, 9.","DOI":"10.3390\/bioengineering9100508"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/archopht.1996.01100130707012","article-title":"Quantitative Videographic Analysis of Blinking in Normal Subjects and Patients with Dry Eye","volume":"114","author":"Tsubota","year":"1996","journal-title":"Arch. Ophthalmol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1089\/ten.tea.2012.0557","article-title":"Platelet-Rich Plasma Exerts Antinociceptive Activity by a Peripheral Endocannabinoid-Related Mechanism","volume":"19","author":"Descalzi","year":"2013","journal-title":"Tissue Eng. Part A"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/jcp.22274","article-title":"Molecular Basis of Anti-Inflammatory Action of Platelet-Rich Plasma on Human Chondrocytes: Mechanisms of NF-\u039aB Inhibition via HGF","volume":"225","author":"Bendinelli","year":"2010","journal-title":"J. Cell. Physiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1177\/0363546511419278","article-title":"Platelet-Rich Plasma Releasate Inhibits Inflammatory Processes in Osteoarthritic Chondrocytes","volume":"39","author":"Koevoet","year":"2011","journal-title":"Am. J. Sports Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1089\/jop.2016.0166","article-title":"The Effect of Immunologically Safe Plasma Rich in Growth Factor Eye Drops in Patients with Sj\u00f6gren Syndrome","volume":"33","author":"Riestra","year":"2017","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s10792-017-0582-7","article-title":"Treatment of Patients with Neurotrophic Keratitis Stages 2 and 3 with Plasma Rich in Growth Factors (PRGF-Endoret) Eye-Drops","volume":"38","author":"Riestra","year":"2018","journal-title":"Int. Ophthalmol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/aos.12012","article-title":"Correlations between Commonly Used Objective Signs and Symptoms for the Diagnosis of Dry Eye Disease: Clinical Implications","volume":"92","author":"Sullivan","year":"2014","journal-title":"Acta Ophthalmol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jtos.2017.05.001","article-title":"Tfos Dews II Diagnostic Methodology Report","volume":"15","author":"Wolffsohn","year":"2017","journal-title":"Ocul. Surf."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/09286580802228509","article-title":"Prevalence of and Associated Factors for Dry Eye in a Spanish Adult Population (The Salnes Eye Study)","volume":"16","author":"Viso","year":"2009","journal-title":"Ophthalmic Epidemiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/OPX.0b013e318181a947","article-title":"Long-Term Incidence of Dry Eye in an Older Population","volume":"85","author":"Moss","year":"2008","journal-title":"Optom. Vis. Sci."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/5\/928\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:33:16Z","timestamp":1760124796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/5\/928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":71,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["medicina59050928"],"URL":"https:\/\/doi.org\/10.3390\/medicina59050928","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,11]]}}}